Overcoming mutation-based resistance to antiandrogens with rational drug design - Abstract

The second-generation antiandrogen enzalutamide was recently approved for patients with castration-resistant prostate cancer.

Despite its success, the duration of response is often limited. For previous antiandrogens, one mechanism of resistance is mutation of the androgen receptor (AR). To prospectively identify AR mutations that might confer resistance to enzalutamide, we performed a reporter-based mutagenesis screen and identified a novel mutation, F876L, which converted enzalutamide into an AR agonist. Ectopic expression of AR F876L rescued the growth inhibition of enzalutamide treatment. Molecular dynamics simulations performed on antiandrogen-AR complexes suggested a mechanism by which the F876L substitution alleviates antagonism through repositioning of the coactivator recruiting helix 12. This model then provided the rationale for a focused chemical screen which, based on existing antiandrogen scaffolds, identified three novel compounds that effectively antagonized AR F876L (and AR WT) to suppress the growth of prostate cancer cells resistant to enzalutamide.

Written by:
Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, Chen Y, Greene GL, Shen Y, Sawyers CL.   Are you the author?
Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan-Kettering Cancer Center, New York, United States; Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, United States.

Reference: Elife. 2013 Apr 9;2:e00499.
doi: 10.7554/eLife.00499

PubMed Abstract
PMID: 23580326

UroToday.com Investigative Urology Section